Floatz logo

DOXORUBICIN

Ovarian Cancer

GenmabSmall moleculePhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
71/ 100
Competitive Position
59/ 100

Competitive context

512 Active assets in the Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
TIL
Inge Marie Svane
Phase 2BB
Olaparib
Shandong University
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Kalinski, Pawel, MD, PhD
Phase 3BB
Carboplatin
Fudan University
Phase 4BB

View all 50 →

Same molecule, other indications

DOXORUBICIN is also rated in:

adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
77 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
76 / 100
View asset →
hematopoietic and lymphoid system neoplasmActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →